Cohen A D, Gopas J, Karplus G, Cohen Y
Department of Oncology, Soroka Medical Center, Beer Sheva, Israel.
Isr J Med Sci. 1995 Feb-Mar;31(2-3):155-9.
Serum testing for the tumor markers CA 15-3 and mucin-like carcinoma-associated antigen (MCA) was performed in 144 patients with breast cancer. Of those patients, 127 were also tested for a third tumor marker, tissue polypeptide-specific antigen (TPS). At the time of testing, 73 patients (51%) were without evidence of disease and 71 patients (49%) had active disease. Mean follow-up time was 16 months. Positivity rates were: 29.8% for CA 15-3, 47.2% for MCA, and 58.3% for TPS. Mean value for patients with no evidence of disease as compared to patients with active disease was 21 U/ml and 117 U/ml for CA 15-3 (P = 0.001), 10.2 kU/l and 22.6 kU/l for MCA (P = 0.001), and 148 U/l and 310 U/l for TPS (P = 0.02). Two year actuarial survival, according to values below and above an established cutoff for CA 15-3 were 80% and 31% (P < 0.001), 75% and 45% for MCA (P < 0.01), and 82% and 50% for TPS (P < 0.01). We conclude that CA 15-3, MCA and TPS values reflect disease state and prognosis in breast cancer patients.
对144例乳腺癌患者进行了肿瘤标志物CA 15 - 3和黏蛋白样癌相关抗原（MCA）的血清检测。其中127例患者还检测了第三种肿瘤标志物，即组织多肽特异性抗原（TPS）。检测时，73例患者（51%）无疾病证据，71例患者（49%）患有活动性疾病。平均随访时间为16个月。阳性率分别为：CA 15 - 3为29.8%，MCA为47.2%，TPS为58.3%。无疾病证据的患者与患有活动性疾病的患者相比，CA 15 - 3的平均值分别为21 U/ml和117 U/ml（P = 0.001），MCA为10.2 kU/l和22.6 kU/l（P = 0.001），TPS为148 U/l和310 U/l（P = 0.02）。根据CA 15 - 3既定临界值上下的数值，两年精算生存率分别为80%和31%（P < 0.001），MCA为75%和45%（P < 0.01），TPS为82%和50%（P < 0.01）。我们得出结论，CA 15 - 3、MCA和TPS值反映了乳腺癌患者的疾病状态和预后。
